Drug intelligence / Profile preview

interferon alpha-2b + interferon gamma

Development stage: Unknown
Lead developer: Center for Genetic Engineering and Biotechnology
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

A combination therapy consisting of interferon alpha-2b and interferon gamma that demonstrates synergistic pharmacodynamic effects. The combination has enhanced antiviral and antiproliferative properties compared to either interferon alone. It has been studied for chronic myelogenous leukemia and SARS-CoV-2 infection, showing improved efficacy in virus elimination and hematologic responses.

Brand names: HeberFERON
Other names: Interferon alfa-2b + interferon gamma

Targets

IFNAR (Immune system modulation via type I interferon receptor)IFNGR1 (Interferon gamma receptor 1)

Beyond the preview

Go deeper on interferon alpha-2b + interferon gamma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alpha-2b + interferon gamma.

Explore the full profile